XYZ-REALITY
16.4.2024 14:02:02 CEST | Business Wire | Press release
XYZ Reality, the leading engineering grade augmented reality (AR) platform for data center and mission critical construction, is proud to announce the appointment of data center industry veterans Christian Belady and Brian Mattson as Strategic Advisors. With their extensive experience and innovative vision, they will help guide XYZ Reality in enhancing its data center construction solution and product roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416398782/en/
Christian Belady (Photo: Business Wire)
Christian Belady, recognized as one of the "5 People who changed the data center" industry, brings a wealth of expertise in managing data center and infrastructure development at a global scale. Formerly Vice President and Distinguished Engineer at Microsoft, Belady developed one of the largest data center footprints in the world. Notably, during his tenure at Hewlett Packard, he was the innovator behind the Power Usage Effectiveness (PUE) metric. His expertise will prove invaluable to XYZ Reality's mission of building it right first time, offering crucial support in product development and sharing invaluable insights and expertise garnered from years of experience in the data center industry.
“I am thrilled to join XYZ Reality as a Strategic Advisor,” said Christian Belady. “At a time when speed to market is paramount, the company’s approach and cutting-edge technology to transforming data center construction and delivery is impressive, and I am eager to contribute to its success with our combined experience and knowledge.”
Brian Mattson brings over 40 years of experience leading large-scale global engineering and construction programs in the semiconductor and data center industries. Prior to joining XYZ Reality, Mattson served in leadership roles at Google, NTT Global Data Centers Americas, and Microsoft. His leadership at Google and Microsoft in global construction and infrastructure supply chain will contribute significantly to XYZ Reality’s growth.
"We are delighted to welcome Christian Belady and Brian Mattson to XYZ Reality as Strategic Advisors," said David Mitchell, Founder & CEO of XYZ Reality. "Their passion, expertise and innovative track record are crucial as we transform the data center industry with our Platform. This collaboration will further enhance our real-time project controls, enabling a proactive approach to construction. Their insights in the mission critical space will streamline processes and boost efficiency as we pioneer proactive solutions in this field.”
Notes to Editor
XYZ Reality is a leading developer of construction technology solutions that give owners and contractors an accurate and objective way to manage and deliver projects. Combining its Engineering Grade AR™ technology and comprehensive Project Controls solution, XYZ gives construction teams the ability to accurately build from holograms of 3D models, and proactively manage their projects with objective real-time insights. This is a revolutionary move away from a reliance on 2D drawings and subjective, out of date data, towards a future where accuracy means each project is built right, first time. The largest developers have implemented XYZ on projects totaling over $10 billion. XYZ is headquartered in London, England with offices around the globe. For more information, visit www.xyzreality.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416398782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
